Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma
Autore:
Peters, JI; Shelledy, DC; Jones, AP; Lawson, RW; Davis, CP; LeGrand, TS;
Indirizzi:
Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA Univ Texas San Antonio TX USA 78284 , Dept Med, San Antonio, TX 78284 USA Univ Texas, Hlth Sci Ctr, Dept Resp Care, Div Pulm Dis Crit Care Med, San Antonio, TX 78284 USA Univ Texas San Antonio TX USA 78284 t Care Med, San Antonio, TX 78284 USA Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA Univ TexasSan Antonio TX USA 78284 Dept Surg, San Antonio, TX 78284 USA
Titolo Testata:
CHEST
fascicolo: 2, volume: 118, anno: 2000,
pagine: 313 - 320
SICI:
0012-3692(200008)118:2<313:ARPSTE>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
INHALED SALMETEROL; BRONCHIAL-ASTHMA; SALBUTAMOL; AGONISTS; BRONCHOCONSTRICTION; XINAFOATE; SYMPTOMS; THERAPY;
Keywords:
asthma; beta-agonists; salmeterol;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Peters, JI S Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp Div, Pulm Dis Sect111E, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA S TexasVet Hlth Care Syst 7400 Merton Minter Blvd San Antonio TX USA 78284
Citazione:
J.I. Peters et al., "A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma", CHEST, 118(2), 2000, pp. 313-320

Abstract

Study objectives: To assess the safety and efficacy of salmeterol xinafoate as an adjunct to conventional therapy for the in-hospital management of acute asthma,Design: A prospective, double-blind, randomized placebo-controlled trial,Setting: Medical wards of a large university-based hospital. Patients: Forty-three patients admitted for an acute exacerbation of asthma,Interventions: Salmeterol (42 mu g) or two puffs of placebo every 12 h in addition to standard therapy (short-acting beta-agonists, corticosteroids, and anticholinergic agents),Results: No clinically adverse effects were seen with the addition of salmeterol to conventional therapy. After salmeterol, there was no difference in pulse, respiratory rate, oxygen saturation by pulse oximetry, severity ofsymptoms, or dyspnea score. Patients receiving salmeterol had greater FEV1percent improvements than the placebo group at 12, 24, 36, and 48 h, Thesefindings were not statistically significant. By paired Student's t tests, there were significant improvements in FEV1 (p = 0.03) and FVC (p = 0.03) in the salmeterol group after 48 h of treatment with no comparable improvement in the placebo group. In a subgroup analysis of patients with an initialFEV1 less than or equal to 1.5 L, the absolute FEV1 percent improvement for salmeterol vs placebo was 51% vs 16% at 24 h and 54% vs 40% at 48 h, The relative FEV1 percent improvement for salmeterol vs placebo was 17% vs 8% at 24 h and 18% vs 14% at 48 h,Conclusion: The addition of salmeterol to conventional therapy is safe andmay benefit hospitalized patients with asthma, Further studies are needed to clarify its role in the treatment of acute exacerbation of asthma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/09/20 alle ore 09:17:53